The Medicines and Healthcare products Regulatory Agency (MHRA) have started publishing weekly summaries of suspected adverse drug reactions (ADRs) associated with the swine 'flu vaccinations.
This area of the MHRA website provides access to the Summary of Product Characteristics and Patient Information Leaflets for Celvapan® and Pandemrix® as well as information about how to report suspected ADRs.
The most recent report includes all suspected ADRs reported up to Thursday 5th November. The report states that, "the most frequently reported suspected adverse reactions are non-serious injection site reactions (e.g. pain, swelling, redness), or are well established minor adverse effects of many vaccines, including the swine flu vaccines (e.g. nausea, vomiting, dizziness muscle pain, fever, fatigue, headache, swollen glands)". They conclude that the balance of benefits and risks of vaccination remain positive.
Action: Clinicians will find this frequently updated report useful when advising patients of the risks and benefits of vaccination.
|« SMC November Update||Eslicarbazepine launched »|